Skip to main content

Ginkgo Bioworks Holdings, Inc.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

DNA$12.01-2.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands except share data)

Three Months Ended June 30, 2025
Common Stock
SharesAmountAdditionalPaid-InCapitalAccumulated DeficitAccumulatedOtherComprehensive(Loss) IncomeTotalStockholders’Equity
Balance as of March 31, 202554,698,246$5$6,576,786$(5,928,514)$(850)$647,427
Issuance of common stock upon exercise or vesting of equity awards624,166—————
Release of 6,647 common shares from escrow related to acquisition——298——298
Issuance of common stock in settlement of purchase price holdback102,9221776——777
Stock-based compensation expense——22,247——22,247
Other comprehensive income————2,5032,503
Net loss———(60,300)—(60,300)
Balance as of June 30, 202555,425,334$6$6,600,107$(5,988,814)$1,653$612,952
Six Months Ended June 30, 2025
Common Stock
SharesAmountAdditionalPaid-InCapitalAccumulated DeficitAccumulatedOtherComprehensive(Loss) IncomeTotalStockholders’Equity
Balance as of December 31, 202454,365,785$5$6,555,416$(5,837,557)$(1,806)$716,058
Issuance of common stock upon exercise or vesting of equity awards956,627—————
Release of 24,913 common shares from escrow related to acquisition——1,237——1,237
Issuance of common stock in settlement of purchase price holdback102,9221776——777
Stock-based compensation expense——42,678——42,678
Other comprehensive income————3,4593,459
Net loss———(151,257)—(151,257)
Balance as of June 30, 202555,425,334$6$6,600,107$(5,988,814)$1,653$612,952

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands except share data)

Three Months Ended June 30, 2024
Common Stock
SharesAmountAdditionalPaid-InCapitalAccumulated DeficitAccumulatedOtherComprehensiveLossTotalStockholders’Equity
Balance as of March 31, 202450,840,607$5$6,445,255$(5,456,439)$(1,551)$987,270
Issuance of common stock upon exercise or vesting of equity awards536,802—14——14
Settlement of contingent consideration49,301—2,570——2,570
Issuance of common stock for asset acquisitions473,717—20,925——20,925
Issuance of common stock in exchange for services68,001—2,500——2,500
Stock-based compensation expense——37,146——37,146
Other comprehensive loss————(172)(172)
Net loss———(217,181)—(217,181)
Balance as of June 30, 202451,968,428$5$6,508,410$(5,673,620)$(1,723)$833,072
Six Months Ended June 30, 2024
Common Stock
SharesAmountAdditionalPaid-InCapitalAccumulated DeficitAccumulatedOtherComprehensiveIncome (Loss)TotalStockholders’Equity
Balance as of December 31, 202350,032,873$5$6,386,191$(5,290,528)$1,484$1,097,152
Issuance of common stock upon exercise or vesting of equity awards991,558—543——543
Settlement of contingent consideration73,958—4,447——4,447
Issuance of common stock for asset acquisitions802,038—36,801——36,801
Issuance of common stock in exchange for services68,001—2,500——2,500
Stock-based compensation expense——77,928——77,928
Other comprehensive loss————(3,207)(3,207)
Net loss———(383,092)—(383,092)
Balance as of June 30, 202451,968,428$5$6,508,410$(5,673,620)$(1,723)$833,072
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.